Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00827177 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA).
- Completed
- Registry status
- Phase 1
- Development phase
- 87
- Enrollment target
NCT00827177 is a Phase 1 study that has completed, run by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA). The registered enrollment target is 87 participants.
The verdict
NCT00827177, a Phase 1 study, has completed, sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 87 participants
- Enrollment target
Study Summary
This is an open-label, dose-escalation study of ARQ 197 administered orally in combination with sorafenib.
Interventions
- DRUG Treatment with ARQ 197 in combination with sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)27 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00827177
The ClinicalTrials.gov registry entry for NCT00827177 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Treatment with ARQ 197 in combination with sorafenib is the first listed.
NCT00827177 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00827177 about?
NCT00827177 is a clinical study titled "Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors". This is an open-label, dose-escalation study of ARQ 197 administered orally in combination with sorafenib.
What is the current status of trial NCT00827177?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2009-09. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00827177?
The interventions under investigation include: Treatment with ARQ 197 in combination with sorafenib (DRUG).
Who is sponsoring clinical trial NCT00827177?
This trial is sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.